BirdflyFeb 24, 2019
RT @nerdabetic: #smartpens I love innovation in pen (MDI) technology as the vast majority of T1s use MDI. This is new pen from @novonordisk which has NFC and can transfer information about injections to @diasend . NovoNordisk also has partnerships with @Roche @mysugr @dexcom #ATTD2019 #attd https://t.co/qtuA0KpJen
Nerdabetic on Twitter

“#smartpens I love innovation in pen (MDI) technology as the vast majority of T1s use MDI. This is new pen from @novonordisk which has NFC and can transfer information about injections to @diasend . NovoNordisk also has partnerships with @Roche @mysugr @dexcom #ATTD2019 #attd https://t.co/qtuA0KpJen”

Twitter
BirdflyFeb 24, 2019
RT @hoodkore: Lots of discussion at #ATTD2019 about glucose time in range (#TIR) and commentary led by Irl Hirsch and Jennifer Sherr just out in Diabetes Care. Access here - https://t.co/R42b485RXh @ADA_DiabetesPro
Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes

The landmark Diabetes Control and Complications Trial (DCCT) identified the relationship between intensive diabetes management for those with type 1 diabetes (T1D) and a delay in the onset or progression of microvascular complications, shifting the paradigm of clinical care for this chronic medical condition (1). Importantly, the data from that trial continue to have a lasting legacy as they can now be analyzed to inform present-day questions. An example of this comes from the article by Beck et al. in this issue of Diabetes Care (2) that concisely states the primary implication of the article in its title, “Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.” In recent years, and with increasing use of continuous glucose monitoring (CGM), the ability to classify sensor glucose levels into various ranges has been feasible. Yet, some have questioned the validity of using these measures as a surrogate outcome measure in ongoing and future clinical trials. Indeed, some have called for a “modern-day” DCCT assessing whether CGM and a greater time in range (TIR) would result in fewer microvascular end points compared with self-monitoring of blood glucose (with intermittent masked CGM). Unfortunately, the duration of time, funds required, and ethical concerns given clinical equipoise regarding the benefits of the technology would make completion of a rigorous randomized controlled trial a near-impossible feat. Recognizing the wealth of data that the DCCT affords, Beck et al. (2) found a creative solution to assess the hypothesis of whether TIR could serve as an outcome measure for future trials. Specifically, they capitalized on the glucose values captured seven times daily every 3 months during the course of the 6+ years of the DCCT. This allowed them to calculate the percent TIR of glucose values between 70 and 180 mg/dL and show a robust …

BirdflyFeb 23, 2019
RT @RenzaS: Question from audience: What are the main reasons why adolescents come out of 670G auto mode? Response: teenager simply silence alarms and don’t act. Surely this suggests that the effort to address the reason for the alarm is too arduous to ‘fix’. #ATTD2019
BirdflyFeb 21, 2019
RT @dcarbohydrated: #wearenotwaiting @OpenAPS featured at #ATTD2019 - “patients are pushing HCPs to be better” https://t.co/9zBUv1q7Ks
Klara Pickova on Twitter

“#wearenotwaiting @OpenAPS featured at #ATTD2019 - “patients are pushing HCPs to be better””

Twitter
BirdflyFeb 20, 2019
RT @antillonendop: #ATTD2019 Children with type 1 diabetes need free Style libre since the first week after diagnosis. It’s a great tool for an adequate process in diabetes education and empowerement @FreeStyleDiabet
BirdflyFeb 20, 2019
RT @drug_czar: David DeJonghe from Lifescan Diabetes @LifescanDI showed at #ATTD2019 this interesting Rock Health data on digital health adoption across US age groups. Millennials will clearly be seeking more digital health than GenX. #wearenotwaiting #doc https://t.co/26oAspBfCE
Matthew Maryniak on Twitter

“David DeJonghe from Lifescan Diabetes @LifescanDI showed at #ATTD2019 this interesting Rock Health data on digital health adoption across US age groups. Millennials will clearly be seeking more digital health than GenX. #wearenotwaiting #doc”

Twitter
BirdflyFeb 20, 2019
RT @CrystalTweetr: 4 a’s of data that can drive outcomes. David Dejonghe from Lifescan. #attd2019 https://t.co/DXwgBsGcHb
Crystal Broj on Twitter

“4 a’s of data that can drive outcomes. David Dejonghe from Lifescan. #attd2019”

Twitter
BirdflyFeb 20, 2019
RT @FreeStyleDiabet: Are you looking to learn more about #FreeStyleLibre2? At the #ATTD2019 you can! Come visit #AbbottDiabetesCare at our #ATTD2019 Exhibition and see it for yourself. #FreestyleDiabet #AlarmScanAct https://t.co/RkWdE99N2e
FreeStyle Libre 2

YouTube
BirdflyFeb 20, 2019
RT @FreeStyleDiabet: New #ATTD2019 abstracts published: Pre-prandial glycemic level and trend associations with post-prandial hyperglycaemia: A
worldwide observational analysis. See the full abstract here: https://t.co/ZflSU8gs9a https://t.co/1xx50WQIm5
ATTD 2019

The 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) is your opportunity to stay up to date and hear the latest cutting-edge advances in our field. See you on 20 -23 February 2019 in Berlin!